Update on patented cholesterol absorption inhibitors

Bibliography

• American heart association statistics committee and stroke subcommittee-2007 update. Dallas, TX: American Heart Association, 2007
   Google Scholar
• Lusis AJ. Atherosclerosis. Nature 2000;407:233-41
   PubMed Web of Science ®Google Scholar
• The Expert panel. Summary of the second report of the national cholesterol education program (NCEP) J Am Med Assoc 1993;269:3015-23
   PubMed Web of Science ®Google Scholar
• Burnett DA. β-Lactam cholesterol absorption inhibitors. Curr Med Chem 2004;11:1873-87
   PubMed Web of Science ®Google Scholar
• Turley SD, Dietschy JM. Sterol absorption by the small intestine. Curr Opin Lipidol 2003;14:233-40
   PubMed Web of Science ®Google Scholar
• Russell DW. Cholesterol biosynthesis and metabolism. Cardiovasc Drugs Ther 1992;6:103-10
   PubMed Web of Science ®Google Scholar
• Maron DJ, Fazio S, Linton MF. Current perspectives on statins. Circulation 2000;101:207-13
   PubMed Web of Science ®Google Scholar
• Zetia (Ezetimibe). FDA drug approvals 2002 Available from: http://www.fda.gov/cder/foi/label/2006/021445s013lbl.pdf [Last accessed 26 March 2009]
   Google Scholar
• Van Heek M, France CF, Compton DS, et al. In vivo mechanism-based discovery of a potent cholesterol absorption inhibitor (SCH-58235) through the identification of the active metabolites of SCH-48461. J Pharmacol Exp Ther 1997;283:157-63
   PubMed Web of Science ®Google Scholar
• Rosenblum SB, Huynh T, Davis HR, et al. Discovery of 1-(4-fluorophenyl)-(3R)-[3-(4-fluorophenyl)-(3S)-hydroxypropyl]-(4S)-(4-hydroxyphenyl)-2-azetidinone (SCH-58235): a designed, potent, orally active inhibitor of cholesterol absorption. J Med Chem 1998;41:973-80
   PubMed Web of Science ®Google Scholar
• Thomas S, Klaus VON. Cholesterol absorption inhibitors for the Treatment of Hypercholesterolaemia. Drugs 2002;62:2333-47
   PubMedGoogle Scholar
• Vytorin (Ezetimibe/Simvastatin). FDA drug approvals. Available from: http://www.fda.gov/cder/foi/label/2004/21687lbl.pdf [Last accessed 26 March 2009]
   Google Scholar
• Beisiegel U. Lipoprotein metabolism. Eur Heart J Suppl 1998;19:A20-3
   Google Scholar
• Shepherd J. The role of the exogenous pathway in hypercholesterolemia. Eur Heart J Suppl 2001;3:E2-5
   Google Scholar
• Russell DW. Cholesterol biosynthesis and metabolism. Cardiovasc Drugs Ther 1992;6:103-10
   PubMed Web of Science ®Google Scholar
• Ikeda I, Matsuoka R, Hamada T, et al. Cholesterol esterase accelerates intestinal cholesterol absorption. Biochim Biophys Acta 2002;1571:34-44
   PubMed Web of Science ®Google Scholar
• David QH. Regulation of intestinal cholesterol absorption. Annu Rev Physiol 2007;69:221-48
   PubMedGoogle Scholar
• Lee RG, Willingham MC, Davis MA, et al. Differential expression of ACAT1 and ACAT2 among cells within liver, intestine, kidney, and adrenal of nonhuman primates. J Lipid Res 2000;4:1991-2001
   Google Scholar
• Clader JW. The discovery of ezetimibe: a view from outside the receptor. J Med Chem 2004;47:1-9
   PubMed Web of Science ®Google Scholar
• Clader JW. Substituted (1,2-Diarylethyl)amide Acyl-CoA: cholesterol acyltransferase inhibitors: effect of polar groups on in vitro and in vivo activity. J Med Chem 1995;38:1600-7
   PubMed Web of Science ®Google Scholar
• Burnett DA, Clader JW, Davis HR. 2-Azetidinones as a inhibitors of cholesterol absorption. J Med Chem 1994;37:1733-36
   PubMed Web of Science ®Google Scholar
• Clader JW, Burnett DA, Caplen MA. 2-Azetidinone cholesterol absorption inhibitors: structure-activity relationships on the heterocyclic nucleus. J Med Chem 1996;39:3694-700
   PubMedGoogle Scholar
• Dugar S, Kirkup M, Clader JW, et al. Gamma-lactams and related compounds as cholesterol absorption inhibitors: homologs of the beta-lactam cholesterol absorption inhibitor SCH-48461. Bioorg Med Chem Lett 1995;5:2947-52
   Web of Science ®Google Scholar
• Bergman M, Morales H, et al. The clinical development of a novel cholesterol absorption inhibitor (abstract). XII International symposium on drugs affecting lipid metabolism 1995;5
   Google Scholar
• Van Heek M, Farley C, Compton DS, et al. Comparison of the activity and disposition of the novel cholesterol absorption inhibitor, SCH-58235, and its glucuronide, SCH-60663. Br J Pharmacol 2000;129:1748-54
   PubMed Web of Science ®Google Scholar
• Gracia CM, Lisnock J, Bull HG, et al. The target of ezetimibe is Niemann Pick C1-like 1 (NPC1L1). Proc Natl Acad Sci USA 2005;102:8132-7
   PubMedGoogle Scholar
• Van Heek M, Farley C, Compton DS, et al. Ezetimibe selectively inhibits intestinal cholesterol absorption in rodents in the presence and absence of exocrine pancreatic function. Br J Pharmacol 2001;134:409-17
   PubMed Web of Science ®Google Scholar
• Van Heek M, Compton DC, Davis HR. The cholesterol absorption inhibitor, ezetimibe, decreases diet-induced hypercholesterolemia in monkeys. Eur J Pharmacol 2001;415:79-84
   PubMed Web of Science ®Google Scholar
• Harry R, Douglas S, Lizbeth H, et al. Ezetimibe, a potent cholesterol absorption inhibitor, inhibits the development of atherosclerosis in ApoE knockout mice. Arterioscler Thromb Vasc Biol 2001;21:2032-38
   PubMedGoogle Scholar
• Catapano AL. Ezetimibe: a selective inhibitor of cholesterol absorption. Eur Heart J Suppl 2001;3:E6-10
   Web of Science ®Google Scholar
• Seedorf U, Thomas E, Aloys L, et al. Cholesterol absorption inhibitor ezetimibe blocks uptake of oxidized LDL in human macrophages. Biochem Biophys Res Comm 2004;320:1337-41
   PubMed Web of Science ®Google Scholar
• Drazen JM, Ware JH, Morrissey S, et al. Ezetimibe and cancer-an uncertain association. N Eng J Med 2008;359:1398-99
   PubMed Web of Science ®Google Scholar
• Peto R, Emberson J, Landray M, et al. Analysis of cancer data from three ezetimibe trials. N Eng J Med 2008;359:1357-66
   PubMed Web of Science ®Google Scholar
• Schering Corporation. Spirocycloalkyl-substituted azetidinones useful as hypocholesterolemic agents. WO1994017038; 1994
   Google Scholar
• Vaccaro WD, Sher R, Davis HR. 2-Azetidinone cholesterol absorption inhibitors: increased potency by substitution of the C-4 phenyl ring. Bioorg Med Chem 1998;6:1429-37
   PubMedGoogle Scholar
• Burnett DA, Margaret EB, Clader JW, et al. Synthesis of fluorescent biochemical tools related to the 2-azetidinone class of cholesterol absorption inhibitors. Bioorg Med Chem Lett 2002;12:315-18
   PubMedGoogle Scholar
• Xu B, Xianxiu X, Renzhong F, et al. Ezetimibe analogs with a reorganized azetidinone ring: Design, synthesis, and evaluation of cholesterol absorption inhibitions. Bioorg Med Chem Lett 2007;17:101-4
   PubMed Web of Science ®Google Scholar
• Wang Y, Zhao R, Zhang H, et al. Design and synthesis of 2-azetidinone cholesterol absorption inhibitors. Lett Drug Des Discov 2008;5:39-42
   Google Scholar
• Carreira M, Werder M, Hauser H, et al. Synthesis and in vitro evaluation of inhibitors of intestinal cholesterol absorption. J Med Chem 2005;48:6035-53
   PubMedGoogle Scholar
• Astrazeneca. Diphenylazetidinone possessing cholesterol absorption inhibitory activity. WO2005061452; 2005
   Google Scholar
• Astrazeneca. Diphenylazetidinone possessing cholesterol absorption inhibitory activity. WO2005061451; 2005
   Google Scholar
• Astrazeneca. Diphenylazetidinone possessing cholesterol absorption inhibitory activity. US20080064676A1; 2008
   Google Scholar
• Schering Corporation. Use of azetidinone compounds. US20070106141; 2007
   Google Scholar
• Astrazeneca. New 2-azetidinone derivatives useful in the treatment of hyperlipidaemic conditions. WO2006137792A1; 2006
   Google Scholar
• Glombik H, Werner K, Stefanie F, et al. Novel diphenylazetidinones, process for their preparation, medicament comprising these compounds and their use. US20020137689; 2007
   Google Scholar
• Sanofi Aventis. Ring substituted azetidinones process for their preparation, medicament comprising these compounds and their use. US7176194; 2007
   Google Scholar
• American Home Products Corporation. Tris carbamic acid esters: inhibitors of cholesterol absorption; inhibitors of ACAT and CEH. EP0635501; 1994
   Google Scholar
• American Home Products Corporation. 4-Carbamoyloxy-piperidine-1-carboxylic acid esters: inhibitors of cholesterol absorption. AU701447; 1995
   Google Scholar
• Pfizer Products. Oxazolidinones as cholesterol absorption inhibitors. WO2008104875A1; 2008
   Google Scholar
• Dugar S, Michael PK, Clader JW, et al. Gamma lactams and related compounds as cholesterol absorption inhibitors: homologs of the beta lactam cholesterol absorption inhibitor SCH-48461. Bioorg Med Chem Lett 1995;5:2947-52
   Web of Science ®Google Scholar
• Tobias R, Lisbet K, Moritz W, et al. Heterocyclic ring scaffolds as small-molecule cholesterol absorption inhibitors. Org Biomol Chem 2005;3:3514-23
   PubMedGoogle Scholar
• Pfefferkorn JA, Larsen SD, Vanhuis C, et al. Substituted oxazolidinones as novel NPC1L1 ligands for the inhibition of cholesterol absorption. Bioorg Med Chem Lett 2008;18:546-53
   PubMedGoogle Scholar
• Vander Jagt DL, Heidrich JE, Linda MC, et al. Inhibition of pancreatic cholesterol esterase reduces cholesterol absorption in the hamster. BMC Pharmacol 2004;4:5-9
   PubMedGoogle Scholar
• Feaster SR, Quinn DM. Mechanism-based inhibitors of mammalian cholesterol esterase. Methods Enzymol 1997;286:231-52
   PubMed Web of Science ®Google Scholar
• Feaster SR, Lee K, Baker N, et al. Molecular recognition by cholesterol esterase of active site ligands: structure-activity effects for inhibition by aryl carbamates and subsequent carbamylenzyme turnover. Biochemistry 1996;35:16723-34
   PubMed Web of Science ®Google Scholar
• Lin G, Shieh C-T, Tsai YC, et al. Structure-reactivity probes for active site shapes of cholesterol esterase by carbamate inhibitors. Biochim Biophys Acta 1999;1431:500-11
   PubMed Web of Science ®Google Scholar
• Deck LM, Baca ML, Salas SL, et al. 3-Alkyl-6-chloro-2-pyrones: selective inhibitors of pancreatic cholesterol esterase. J Med Chem 1999;42:4250-6
   PubMed Web of Science ®Google Scholar
• Vander Jagt DL, Heynekamp JJ, Hunsaker LA, et al. Isocoumarin-based inhibitors of pancreatic cholesterol esterase. Bioorg Med Chem 2008;16:5285-94
   PubMedGoogle Scholar
• Pietsch M, Gutschow M. Alternate substrate inhibition of cholesterol esterase by thieno[2,3-d][1,3]oxazin-4-ones. J Biol Chem 2002;277:24006-13
   PubMed Web of Science ®Google Scholar
• Pietsch M, Gutschow M. Synthesis of tricyclic 1,3-oxazin-4-ones and kinetic analysis of cholesterol esterase and acetylcholinesterase inhibition. J Med Chem 2005;48:8270-88
   PubMed Web of Science ®Google Scholar
• Schaloske RH, Dennis EA. The phospholipase A2 superfamily and its group numbering. Biochim Biophys Acta 2006;1761:1246-59
   Google Scholar
• Rampone AJ, Machida CM. Mode of action of lecithin in suppressing cholesterol absorption. J Lipid Res 1981;22:744-52
   PubMed Web of Science ®Google Scholar
• Rampone AJ, Long LR. The effect of phosphatidylcholine and lysophosphatidylcholine on the absorption and mucosal metabolism of oleic acid and cholesterol in vitro. Biochim Biophys Acta 1977;486:500-10
   PubMed Web of Science ®Google Scholar
• Hanasaki K, Yamada K, Yamamoto S, et al. Potent modification of low density lipoprotein by group X secretory phospholipase A2 is linked to macrophage foam cell formation. J Biol Chem 2002;277:29116-24
   PubMed Web of Science ®Google Scholar
• Kolodgie FD, Burke AP, Skorija KS, et al. Lipoprotein-associated phospholipase A2 protein expression in the natural progression of human coronary atherosclerosis. Arterioscler Thromb Vasc Biol 2006;26:2523-29
   PubMed Web of Science ®Google Scholar
• Warner-Lambert Company. PLA2 inhibitors and their use for inhibition of intestinal cholesterol absorption. US5504073; 1996
   Google Scholar
• Smithkline Beecham PLC. 2,5-substituted-1-(aminocarbonylalkyl)-pyrimidin-4-one derivatives with LpPLA2, inhibitory activity for the treatment of atherosclerosis. WO2003015786; 2003
   Google Scholar
• Smith SA, Stansfield IG, Stanway SJ, et al. The discovery of SB-435495: a potent, orally active inhibitor of lipoprotein-associated phospholipase A2 for evaluation in man. Bioorg Med Chem Lett 2002;12:2603-6
   PubMedGoogle Scholar
• Smith SA, Stansfield IG, Stanway SJ, et al. The identification of clinical candidate SB-480848: A potent inhibitor of lipoprotein-associated phospholipase A2. Bioorg Med Chem Lett 2003;13:1067-70
   PubMedGoogle Scholar
• Mohler ER, Ballantyne CM, Davidson MH, et al. The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, double-blind, placebo-controlled study. J Am Coll Cardiol 2008;51:1632-41
   PubMed Web of Science ®Google Scholar
• Clinical trials of SB-480848. Available from: http://clinicaltrials.gov/ ct2/show/NCT00269048 [Last accessed 26 March 2009]
   Google Scholar
• Rosenson RS, Mcconnell D, Elliott M, et al. Effects of 1H-indole-3-glyoxamide (A-002) on concentration of secretory phospholipase A2 (PLASMA study): a phase II double-blind, randomised, placebo-controlled trial. Lancet 2009;373:649-58
   PubMed Web of Science ®Google Scholar
• Corson MA. Phospholipase A2 inhibitors in atherosclerosis: the race is on. Lancet 2009;373:608-10
   PubMedGoogle Scholar
• Clinical trials of A-002. Available from: http://clinicaltrials.gov/ct2/show/NCT00525954?term = A-002&rank = 1 [Last accessed 26 March 2009]
   Google Scholar
• Waddah AA, Gill RK. Bile acid transporters: structure, function, regulation and pathophysiological implications. Pharm Res 2007;24:1803-22
   PubMedGoogle Scholar
• Kramer W, Buscher HP, Gerok W, et al. Bile salt binding to serum components. Eur J Biochem 1979;102:1-9
   PubMedGoogle Scholar
• Kramer W. Identification of the bile acid binding proteins in human serum by photoaffinity labeling. Biochim Biophys Acta 1995;1257:230-8
   PubMedGoogle Scholar
• Chiang JYJ. Regulation of bile acid synthesis: pathways, nuclear receptors, and mechanisms. J Hepatol 2004;40:539-51
   PubMed Web of Science ®Google Scholar
• Glaxo Wellcome, Inc. Hypolipidemic benzothiazepine compounds. US5859240; 1999
   Google Scholar
• Tollefson MB, Vernier WF, Huang H, et al. A novel class of apical sodium co-dependent bile acid transporter inhibitors: the 2,3-disubstituted-4-phenylquinolines. Bioorg Med Chem Lett 2000;10:277-9
   PubMed Web of Science ®Google Scholar
• Tollefson MB, Stephen AK, Theresa RF, et al. A novel class of apical sodium co-dependent bile acid transporter inhibitors: the 1,2-Benzothiazepines. Bioorg Med Chem Lett 2003;13:3727-30
   PubMed Web of Science ®Google Scholar
• Tremont SJ, Lee LF, Huang HC, et al. Discovery of potent, nonsystemic apical sodium co-dependent bile acid transporter inhibitors (Part 1). J Med Chem 2005;48:5837-52
   PubMedGoogle Scholar
• Kitayama K, Nakai D, Kono K, et al. Novel non-systemic inhibitor of ileal apical Na+ -dependent bile acid transporter reduces serum cholesterol levels in hamsters and monkeys. Eur J Pharmacol 2006;539:89-98
   PubMed Web of Science ®Google Scholar
• Insull WJ. Clinical utility of bile acid sequestrants in the treatment of dyslipidemia: a specific review. South Med J 2006;99:257-73
   PubMed Web of Science ®Google Scholar
• Davidson MH, Dillon MS, Gordon B, et al. Colesevelam hydrocholoride (cholestragel): a new potent bile acid sequesterants associated with a low incidence of gastrointestinal side effect. Arch Intern Med 1999;159:1893-900
   PubMed Web of Science ®Google Scholar
• Clinical trials of colesevelam and ezetimibe combination. Available from: http://clinicaltrials.gov/ct2/show/NCT00185107?term = colesevelam + alone&rank = 4 [Last accessed 26 March 2009]
   Google Scholar
• Werner K, Glombik H. Bile acid reabsorption inhibitors (BARI): novel hypolipidemic frugs. Curr Med Chem 2006;13:997-1016
   PubMedGoogle Scholar
• Buhman KF, Accad M, Farese RV. Mammalian acyl-CoA:cholesterol acyltransferases. Biochim Biophys Acta 2000;1529:142-54
   PubMed Web of Science ®Google Scholar
• Chang TY, Chang CCY, Cheng D. Acyl-coenzyme A: cholesterol acyltransferase. Annu Rev Biochem 1997;66:613-38
   PubMed Web of Science ®Google Scholar
• Oelkers P, Behari A, Cromley D, et al. Characterization of two human gene encoding acyl coenzyme A-cholesterol acyl transferase related enzymes. J Biol Chem 1998;273:26765-78
   PubMed Web of Science ®Google Scholar
• Kushwaha RS, Rosillo A, Roderiguex R, et al. Expression levels of ACAT1 and ACAT2 genes in the liver and intestine of baboons with high and low lipemic responses to dietary lipids. J Nutr Biochem 2005;16:714-21
   PubMedGoogle Scholar
• Akira M, Naomi S, Kiyoshi T, et al. Expression of ACAT-1 protein in human atherosclerotic lesions and cultured human monocytes-macrophages. Arterioscler Thromb Vasc Biol 1998;18:1568-74
   PubMedGoogle Scholar
• Suckling KE, Stange EF. Role of acyl-CoA cholesterol acyltransferase in cellular cholesterol metabolism. J Lipid Res 1985;26:647-71
   PubMed Web of Science ®Google Scholar
• American Home Products Corporation. N,N',N'-trisubstituted-5-bisaminomethylene-1,3-dioxane-4, 6-dione inhibitors of acyl-coa:cholesterol-acyl transferase. US5179216; 1993
   Google Scholar
• Kusunoki J, Aragane K, Yamaura T, et al. Studies on acyl-CoA: cholesterol acyltransferase (ACAT) inhibitory effects and enzyme selectivity of F-1394, a pantotheic acid derivative. Jap J Pharmacol 1995;67:195-203
   PubMedGoogle Scholar
• Kumazawa T, Yanase M, Shirakura S, et al. Inhibitors of acyl-CoA: cholesterol acyltransferase. II. Preparation and hypocholesterolemic activity of optically active dibenz[b,e]oxepi-11-carboxanilides. Chem Pharm Bull 1996;44:222-5
   PubMedGoogle Scholar
• Burnett JR, Huff MW. Avasimibe (Pfizer). Curr Opin Investig Drugs 2002;3:1328-33
   PubMedGoogle Scholar
• Delsing DJM, Offerman EH, Duyvenvoorde W, et al. Acyl-CoA: cholesterol acyltransferase inhibitor avasimibe reduces atherosclerosis in addition to its cholesterol-lowering effect in ApoE*3-leiden mice. Circulation 2001;103:1778-86
   PubMed Web of Science ®Google Scholar
• Nissen SE, Tuzcu EM, Brewer HB, et al. Effect of ACAT inhibition on the progression of coronary atherosclerosis. N Engl J Med 2004;354:1253-63
   Google Scholar
• Fazio S, Linton M. Failure of ACAT inhibition to retard atherosclerosis. N Engl J Med 2004;354:1307-9
   Google Scholar
• Terasaka N, Miyazakib A, Kasanuki N, et al. ACAT inhibitor pactimibe sulfate (CS-505) reduces and stabilizes atherosclerotic lesions by cholesterol-lowering and direct effects in apolipoprotein E-deficient mice. Atherosclerosis 2007;190:239-47
   PubMedGoogle Scholar
• Clinical trials of pactimibe. Available from: http://clinicaltrials.gov/ct2/show/NCT00185042?term = pactimibe&rank = 1 [Last accessed 26 March 2009]
   Google Scholar
• Ikenoya M, Yoshinaka Y, Kobayashi H, et al. A selective ACAT-1 inhibitor, K-604, suppresses fatty streak lesions in fat-fed hamsters without affecting plasma cholesterol levels. Atherosclerosis 2007;191:290-7
   PubMedGoogle Scholar
• Clinical trials of K-604. Available from: http://clinicaltrials.gov/ct2/show/NCT00851500?term = K604&rank = 1 [Last accessed 25 February 2009]
   Google Scholar
• Takeda Pharmaceutical Company Limited. Coumarin derivative process, process for their production and use thereof. US20070179154; 2007
   Google Scholar
• Ikeda I, Tanaka K, Sugano M, et al. Discrimination between cholesterol and sitosterol for absorption in rats. J Lipid Res 1988;29:1583-91
   PubMed Web of Science ®Google Scholar
• Davis HR, Zhu LJ, Hoos LM, et al. Niemann-Pick C1 Like 1 (NPC1L1) is the intestinal phytosterol and cholesterol transporter and a key modulator of whole body cholesterol homeostasis. J Biol Chem 2004;279:33586-92
   PubMed Web of Science ®Google Scholar
• Berge KE, Tian H, Graf GA, et al. Accumulation of dietary cholesterol in sitosterolemia caused by mutations in adjacent ABC transporters. Science 2000;290:1771-5
   PubMed Web of Science ®Google Scholar
• Ge L, Wang J, Qi W, et al. The cholesterol absorption inhibitor ezetimibe acts by blocking the sterol-induced internalization of NPC1L1. Cell Metab 2008;7:508-19
   PubMed Web of Science ®Google Scholar
• Ling WH, Jones PJ. Dietary phytosterols: a review of metabolism, benefits and side effects. Life Sci 1995;57:195-206
   PubMed Web of Science ®Google Scholar
• Sugano M, Morioka H, Ikeda I. A comparison of hypocholesterolemic activity of beta-sitosterol and beta-sitostanol in rats. J Nutr 1977;107:2011-9
   PubMed Web of Science ®Google Scholar
• Burnett J. FM-VP4 (Forbes Medi-Tech). Curr Opin Investig Drugs 2003;4:1120-5
   PubMedGoogle Scholar
• Wasan KM, Najafi S, Wong J, et al. Assessing plasma lipid levels, body weight, and hepatic and renal toxicity following chronic oral administration of water soluble Phytosterol compound, FM-VP4 to gerbils. J Pharm Sci 2001;4:228-34
   Web of Science ®Google Scholar
• Wasan KM, Najafi S, Zamfir C, et al. Assessing the plasma pharmacokinetics, tissue distribution, excretion and effects on cholesterol pharmacokinetics of novel hydrophilic compound, FM-VP4, following administration to rats. J Pharm Sci 2001;4:207-16
   Google Scholar